Haemonetics Corporation (NYSE:HAE) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• According to analysts, Haemonetics Corporation (NYSE:HAE) has a consensus rating of "Moderate Buy", with seven analysts recommending buy and one assigning a strong buy rating.
• Haemonetics reported $1.10 earnings per share for the last quarter, exceeding analyst expectations and generating a revenue of $321.39 million.
• The stock's average one-year price target among brokers is $78.78, while Haemonetics' shares recently opened at $50.54, reflecting a 1.2% decline.

Haemonetics Corporation (NYSE:HAE - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $78.7778.

HAE has been the subject of a number of research reports. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $62.00 price objective (down previously from $85.00) on shares of Haemonetics in a research report on Friday, August 8th. Barrington Research reduced their price objective on Haemonetics from $95.00 to $86.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. Raymond James Financial downgraded Haemonetics from a "strong-buy" rating to an "outperform" rating and reduced their price objective for the stock from $105.00 to $78.00 in a research report on Monday, August 11th. Needham & Company LLC reiterated a "buy" rating and issued a $68.00 price objective (down previously from $84.00) on shares of Haemonetics in a research report on Thursday, August 7th. Finally, Robert W. Baird began coverage on Haemonetics in a research report on Thursday, June 26th. They issued an "outperform" rating and a $87.00 price objective for the company.

Hedge Funds Weigh In On Haemonetics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Quarry LP lifted its position in shares of Haemonetics by 63.4% during the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock worth $31,000 after buying an additional 192 shares during the period. EverSource Wealth Advisors LLC lifted its position in shares of Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier's stock worth $31,000 after buying an additional 396 shares during the period. GAMMA Investing LLC lifted its position in shares of Haemonetics by 59.4% during the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier's stock worth $33,000 after buying an additional 165 shares during the period. UMB Bank n.a. lifted its position in shares of Haemonetics by 91.7% during the 2nd quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier's stock worth $50,000 after buying an additional 320 shares during the period. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of Haemonetics during the 2nd quarter worth approximately $64,000. Institutional investors own 99.67% of the company's stock.

Haemonetics Stock Performance

HAE traded up $0.68 during midday trading on Monday, reaching $51.28. The company's stock had a trading volume of 957,340 shares, compared to its average volume of 1,034,440. The stock has a market cap of $2.47 billion, a P/E ratio of 10.88, a PEG ratio of 0.93 and a beta of 0.39. The company has a fifty day simple moving average of $60.69 and a 200 day simple moving average of $64.72. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04. Haemonetics has a twelve month low of $49.43 and a twelve month high of $94.99.

Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.01 by $0.09. The firm had revenue of $321.39 million for the quarter, compared to analyst estimates of $305.12 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The company's revenue was down 4.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.02 EPS. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. Research analysts expect that Haemonetics will post 4.55 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.